Advertisement

Topics

Midatech Group Ltd. Company Profile

08:25 EST 15th December 2018 | BioPortfolio

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications for a number of industry segments including life sciences, electronics and fine chemicals.

Founded in 2000, Midatech Ltd is a private company headquartered in Abingdon, Oxford, UK. In 2005, it registered its manufacturing facility – Midatech Biogune S.L. – in Bilbao, Spain, which became fully operational for cGMP standard design and manufacturing of API nanoparticles in March 2007. In 2008, Midatech Ltd further expanded with the opening of PharMida AG in Basel, Switzerland, which is responsible for clinical development of Midatech’s products.

Midatech’s biocompatible nanoparticles possess a number of unique properties that make them ideal for diagnostic and therapeutic applications. The nanoparticles are water dispersible and can be designed to diffuse freely in vivo, or to target specific cells. With a diameter of less than five nm, unbound nanoparticles are rapidly excreted by the kidneys, and thereby reduce the likelihood of non-specific in vivo accumulation. Their small size potentially enables drug delivery via different routes of administration, including parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation. Furthermore, their high-degree of stability to enzymatic digestion makes them attractive for oral administration. The nanoparticles can be designed to attaching multiple ligands to the nanoparticle surface, thereby allowing multivalent drug or multi-drug delivery on a single particle. Owing to the fact that the nanoparticles self-assemble in a single synthetic step, commercial manufacturing is straightforward, safe, scalable and low cost.

Midatech Ltd. has exclusive world-wide IP for the technology covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas as well as in other industries. It also has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles.
 

Location

4 & 5 Dunmore Court
Wootton Road
Abingdon
Oxfordshire
OX13 6BH
UK

Contact

Phone: +44 1235 528 022
Fax: + 44 1235 528 023
Email: info@midatechgroup.com


News Articles [715 Associated News Articles listed on BioPortfolio]

Midatech: The Story of a Nanoparticle Start-Up

In this exclusive interview, Fintan Walton talks to Tom Rademacher, President of Midatech, about the formation of the biotech, Professor Rademacher's fifth start-up company. Tom discusses Midatech's b...

Midatech Announces Proposed Sale of Midatech Pharma US Inc. (“MTP US”) to Kanwa Holdings, LP an affiliate of Barings LLC

27 September 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Announces Proposed Sale of Midatech Pharma US Inc. (“MTP US”) to Kanwa Holdings, LP an affiliate of Barings LLC T...

Strong sales ''a good validation'' for Midatech Pharma Plc's entry into the US

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) reported a tenfold year-on-year increase in revenue in the first half of 2016. Much of the increase was down to the group's acquisition of  cancer s...

Midatech Pharma to co-promote Bausch Health's NeutraSal in the US

Bausch Health Companies Inc. (formerly Valeant) is licensing Midatech Pharma PLC’s Midatech Pharma US Inc. subsidiary exclusive rights to promote its supersaturated calcium product NeutraSal rinse i...

Zak Mir: Midatech Pharma looking upwards if it breaks 50-day trend

Midatech Pharma Inc (LON:MTPH) can look towards 118p if it can break through the 50-day moving average suggests technical analyst Zak Mir.

New loan for Midatech promises greater profitability

Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising...

Midatech Pharma “delighted” with first-in-human data for MTD201 drug

While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

Midatech Pharma “delighted” with first in-human data for MTD201 drug

While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

PubMed Articles [1747 Associated PubMed Articles listed on BioPortfolio]

Does Timing of Surgery Affect Treatment of the Terrible Triad of the Elbow?

BACKGROUND This study investigated the influence of surgical timing on the treatment of terrible triad of the elbow (TTE). MATERIAL AND METHODS After exclusion, 63 patients were enrolled in this study...

Isolation and exploitation of minority: Game theoretical analysis.

We investigate various group-size distributions occurring in a situation where each group's resource is exposed to appropriation by other groups. The amount of appropriation depends on the size differ...

Group I introns are widespread in archaea.

Group I catalytic introns have been found in bacterial, viral, organellar, and some eukaryotic genomes, but not in archaea. All known archaeal introns are bulge-helix-bulge (BHB) introns, with the exc...

The role of group cohesion in a group-based behavioral weight loss intervention.

Behavioral weight loss interventions are often delivered in groups. Group cohesion may enhance program attendance and, thereby, weight loss. In this secondary analysis, our goals were to: (1a) assess ...

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma.

The synergistic effects of docetaxel (DTX) combined with carboplatin in the treatment of retinoblastoma (RB) was explored in mouse RB xenografts compared with carboplatin alone and DTX alone groups. R...

Clinical Trials [4119 Associated Clinical Trials listed on BioPortfolio]

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Ultrasound and Exercises in Knee Osteoarthritis

The aim of this investigation is to compare the effects of continuous (CUS) and pulsed (PUS) ultrasound associated with a program of exercises on pain, range of motion, muscle strength, fu...

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

The T2T Study of RA Based on SSDM

This study evaluate the Smart System of Disease Management(SSDM)to improve the treat-to-target(T2T) and the safety of drug in the treatment of rheumatoid(RA). All participants will be ...

Companies [1643 Associated Companies listed on BioPortfolio]

Midatech Ltd.

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products w...

Midatech Group Ltd.

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel character...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Midatech Group Ltd." on BioPortfolio

We have published hundreds of Midatech Group Ltd. news stories on BioPortfolio along with dozens of Midatech Group Ltd. Clinical Trials and PubMed Articles about Midatech Group Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Midatech Group Ltd. Companies in our database. You can also find out about relevant Midatech Group Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record